The administration of albiflorin 50 mg/kg and MCC950 (a selective inhibitor of the NOD-like receptor protein 3 (NLRP3) inflammasome) at a dose of 10 mg/kg for 15 days led to a number of improvements thereafter, including the alleviation of CCI-induced mechanical allodynia, comorbid anxiety, and depression-like behavior, as determined by the Von Frey test, the open field test, the elevated plus maze test, and the forced swim test [81]. This evidence concerns the gene NLRP3 and depressive symptom measurement.